Genentech and PeptiDream to co-develop radiopharmaceuticals in $1BN deal
The Roche-owned U.S. giant Genentech has teamed up with the Japanese biotech Peptidream to co-develop peptide-based radiopharmaceutical treatments.
Patrick Reid Fusion Pharmaceuticals Peptide Discovery Platform System Ono Pharmaceutical Markets Amp Regulations Emerging Markets
Source: biopharma-reporter.com